Nisa Investment Advisors LLC Increases Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Nisa Investment Advisors LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,323 shares of the medical equipment provider’s stock after purchasing an additional 1,036 shares during the period. Nisa Investment Advisors LLC’s holdings in Zimmer Biomet were worth $5,882,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Wealthfront Advisers LLC lifted its stake in Zimmer Biomet by 28.2% in the 2nd quarter. Wealthfront Advisers LLC now owns 4,877 shares of the medical equipment provider’s stock valued at $445,000 after buying an additional 1,074 shares in the last quarter. Resonant Capital Advisors LLC lifted its position in shares of Zimmer Biomet by 8.0% in the second quarter. Resonant Capital Advisors LLC now owns 4,771 shares of the medical equipment provider’s stock valued at $436,000 after acquiring an additional 354 shares in the last quarter. Leeward Investments LLC MA lifted its position in shares of Zimmer Biomet by 2.0% in the second quarter. Leeward Investments LLC MA now owns 96,140 shares of the medical equipment provider’s stock valued at $8,769,000 after acquiring an additional 1,853 shares in the last quarter. Brighton Jones LLC lifted its position in shares of Zimmer Biomet by 174.9% in the second quarter. Brighton Jones LLC now owns 5,202 shares of the medical equipment provider’s stock valued at $474,000 after acquiring an additional 3,310 shares in the last quarter. Finally, MQS Management LLC purchased a new position in Zimmer Biomet in the 2nd quarter valued at $490,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $101.18 on Wednesday. The company’s 50 day simple moving average is $101.81 and its 200-day simple moving average is $97.63. The company has a market capitalization of $20.04 billion, a price-to-earnings ratio of 24.62, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Analysts Set New Price Targets

A number of brokerages have weighed in on ZBH. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target on the stock. Evercore ISI decreased their price target on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 7th. BTIG Research raised their target price on shares of Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a research note on Monday, October 13th. Finally, Raymond James Financial raised their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $111.94.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.70% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.